Références

1. DeGuire J,
2. Clarke J,
3. Rouleau K,
4. et al

. Blood pressure and hypertension. Health Rep 2019;30:14–21.

1. Leung AA,
2. Williams JVA,
3. McAlister FA,
4. et al

.; Hypertension Canada’s Research and Evaluation Committee. Worsening hypertension awareness, treatment, and control rates in Canadian women between 2007 and 2017. Can J Cardiol 2020;36:732–9.

1. Leung AA,
2. Williams JVA,
3. Padwal RS,
4. et al

. Prevalence, patient awareness, treatment, and control of hypertension in Canadian adults with common comorbidities. CJC Open 2024;6:1099–107.

1. Leung AA,
2. Bell A,
3. Tsuyuki RT,
4. et al

. Refocusing on hypertension control in Canada. CMAJ 2021;193:E854–5.

1. Goupil R,
2. Tsuyuki RT,
3. Terenzi KA,
4. et al

. Ushering in a new era of hypertension Canada guidelines: a roadmap of what lies ahead. Can J Cardiol 2025;41:159–62.

1. Jaffe MG,
2. Lee GA,
3. Young JD,
4. et al

. Improved blood pressure control associated with a large-scale hypertension program. JAMA 2013;310:699–705.

1. Jaffe MG,
2. Young JD

. The Kaiser Permanente Northern California story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013). J Clin Hypertens (Greenwich) 2016;18:260–1.

1. Campbell NRC,
2. Ordunez P,
3. Giraldo G,
4. et al

. WHO HEARTS: a global program to reduce cardiovascular disease burden — experience implementing in the Americas and opportunities in Canada. Can J Cardiol 2021;37:744–55.

1. Butalia S,
2. Audibert F,
3. Cote AM,
4. et al

.; Hypertension Canada. Hypertension Canada’s 2018 guidelines for the management of hypertension in pregnancy. Can J Cardiol 2018;34:526–31.

1. Dionne JM,
2. Harris KC,
3. Benoit G,
4. et al

.; Hypertension Canada Guideline Committee. Hypertension Canada’s 2017 guidelines for the diagnosis, assessment, prevention, and treatment of pediatric hypertension. Can J Cardiol 2017; 33:577–85.

1. Guyatt GH,
2. Oxman AD,
3. Vist GE,
4. et al

.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.

1. Muntner P,
2. Shimbo D,
3. Carey RM,
4. et al

. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension 2019;73:e35–66.

1. Stergiou GS,
2. Alpert B,
3. Mieke S,
4. et al

. A universal standard for the validation of blood pressure measuring devices: association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) collaboration statement. Hypertension 2018;71:368–74.

1. Picone DS,
2. Campbell NRC,
3. Schutte AE,
4. et al

. Validation status of blood pressure measuring devices sold globally. JAMA 2022;327:680–1.

1. Chan JCH,
2. Vandermeer I,
3. Picone DS,
4. et al

. Validity of home blood pressure devices sold in Canada. CJC Open 2024;6:54–6.

1. Cheung AK,
2. Whelton PK,
3. Muntner P,
4. et al

. International consensus on standardized clinic blood pressure measurement: a call to action. Am J Med 2023; 136:438–45.e1.

1. Pappaccogli M,
2. Di Monaco S,
3. Perlo E,
4. et al

. Comparison of automated office blood pressure with office and out-off-office measurement techniques. Hypertension 2019;73:481–90.

1. Roerecke M,
2. Kaczorowski J,
3. Myers MG

. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med 2019;179:351–62.

1. Drawz PE,
2. Agarwal A,
3. Dwyer JP,
4. et al

. Concordance between blood pressure in the systolic blood pressure intervention trial and in routine clinical practice. JAMA Intern Med 2020;180:1655–63.

1. Einstadter D,
2. Bolen SD,
3. Misak JE,
4. et al

. Association of repeated measurements with blood pressure control in primary care. JAMA Intern Med 2018;178:858–60.

1. Zhang W,
2. Zhang S,
3. Deng Y,
4. et al

. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 2021;385:1268–79.

1. Liu J,
2. Li Y,
3. Ge J,
4. et al

.; ESPRIT Collaborative Group. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet 2024;404:245–55.

1. Bi Y,
2. Li M,
3. Liu Y,
4. et al

.; BPROAD Research Group. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med 2025;392:1155–67.

1. Rabi DM,
2. McBrien KA,
3. Sapir-Pichhadze R,
4. et al

. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol 2020; 36:596–624.

1. Staplin N,
2. de la Sierra A,
3. Ruilope LM,
4. et al

. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet 2023;401:2041–50.

1. Franklin SS,
2. Thijs L,
3. Hansen TW,
4. et al

. White-coat hypertension: new insights from recent studies. Hypertension 2013;62:982–7.

1. Thakkar HV,
2. Pope A,
3. Anpalahan M

. Masked hypertension: a systematic review. Heart Lung Circ 2020;29:102–11.

1. Guirguis-Blake JM,
2. Evans CV,
3. Webber EM,
4. et al

. Screening for hypertension in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2021;325:1657–69.

1. Rapsomaniki E,
2. Timmis A,
3. George J,
4. et al

. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014;383:1899–911.

1. Guo X,
2. Zhang X,
3. Guo L,
4. et al

. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Curr Hypertens Rep 2013;15:703–16.

1. Whelton PK,
2. O’Connell S,
3. Mills KT,
4. et al

. Optimal antihypertensive systolic blood pressure: a systematic review and meta-analysis. Hypertension 2024;81:2329–39.

1. Verdecchia P,
2. Staessen JA,
3. Angeli F,
4. et al

.; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525–33.

1. Huang L,
2. Trieu K,
3. Yoshimura S,
4. et al

. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ 2020;368:m315.

1. Neal B,
2. Wu Y,
3. Feng X,
4. et al

. Effect of salt substitution on cardiovascular events and death. N Engl J Med 2021;385:1067–77.

1. Mattes RD,
2. Donnelly D

. Relative contributions of dietary sodium sources. J Am Coll Nutr 1991;10:383–93.

1. Mente A,
2. O’Donnell M,
3. Rangarajan S,
4. et al

. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet 2018;392:496–506.

1. O’Donnell M,
2. Mente A,
3. Rangarajan S,
4. et al

. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 2014;371:612–23.

1. Semlitsch T,
2. Krenn C,
3. Jeitler K,
4. et al

. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 2021;2:CD008274.

1. Wilding JPH,
2. Batterham RL,
3. Calanna S,
4. et al

.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989–1002.

1. Fagard RH,
2. Cornelissen VA

. Effect of exercise on blood pressure control in hypertensive patients. Eur J Cardiovasc Prev Rehabil 2007;14:12–7.

1. Roerecke M,
2. Kaczorowski J,
3. Tobe SW,
4. et al

. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2017;2:e108–20.

1. Liu F,
2. Liu Y,
3. Sun X,
4. et al

. Race- and sex-specific association between alcohol consumption and hypertension in 22 cohort studies: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 2020;30:1249–59.

1. Primatesta P,
2. Falaschetti E,
3. Gupta S,
4. et al

. Association between smoking and blood pressure: evidence from the health survey for England. Hypertension 2001;37:187–93.

1. Yang JJ,
2. Yu D,
3. Shu X-O,
4. et al

. Reduction in total and major cause-specific mortality from tobacco smoking cessation: a pooled analysis of 16 population-based cohort studies in Asia. Int J Epidemiol 2022;50:2070–81.

1. Sundström J,
2. Arima H,
3. Jackson R,
4. et al

.; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184–91.

1. D’Agostino RB Sr.,
2. Vasan RS,
3. Pencina MJ,
4. et al

. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–53.

1. McEvoy JW,
2. McCarthy CP,
3. Bruno RM,
4. et al

.; ESC Scientific Document Group. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45:3912–4018.

1. Thomopoulos C,
2. Parati G,
3. Zanchetti A

. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 2017;35:2150–60.

1. Beddhu S,
2. Chertow GM,
3. Cheung AK,
4. et al

.; SPRINT Research Group. Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. Circulation 2018;137:134–43.

1. Law MR,
2. Wald NJ,
3. Morris JK,
4. et al

. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427.

1. Ettehad D,
2. Emdin CA,
3. Kiran A,
4. et al

. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957–67.

1. Wiysonge CS,
2. Bradley H,
3. Mayosi BM,
4. et al

. Beta-blockers for hypertension. Cochrane Database Syst Rev 2017;(1):CD002003.

1. Andrade JG,
2. Aguilar M,
3. Atzema C,
4. et al

.; Members of the Secondary Panel. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol 2020;36:1847–948.

1. McDonald M,
2. Virani S,
3. Chan M,
4. et al

. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 2021;37:531–46.

1. Fitton CA,
2. Steiner MFC,
3. Aucott L,
4. et al

. In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. J Hypertens 2017;35:2123–37.

1. Ishani A,
2. Cushman WC,
3. Leatherman SM,
4. et al

.; Diuretic Comparison Project Writing Group. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med 2022;387:2401–10.

1. Gu Q,
2. Burt VL,
3. Dillon CF,
4. et al

. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012;126:2105–14.

1. Parati G,
2. Kjeldsen S,
3. Coca A,
4. et al

. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension 2021;77:692–705.

1. Salam A,
2. Kanukula R,
3. Atkins E,
4. et al

. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2019;37:1768–74.

1. Gupta AK,
2. Arshad S,
3. Poulter NR

. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399–407.

1. Rea F,
2. Corrao G,
3. Merlino L,
4. et al

. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension 2018;72:846–53.

1. Stankus V,
2. Hemmelgarn B,
3. Campbell NR,
4. et al

. Reducing costs and improving hypertension management. Can J Clin Pharmacol 2009;16:e151–5.

1. MacDonald TM,
2. Williams B,
3. Webb DJ,
4. et al

.; British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017;6:e006986.

1. Egan BM,
2. Bandyopadhyay D,
3. Shaftman SR,
4. et al

. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59:1124–31.

1. Fried LF,
2. Emanuele N,
3. Zhang JH,
4. et al

.; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–903.

1. Ojji DB,
2. Salam A,
3. Sani MU,
4. et al

. Low-dose triple-pill vs standard-care protocols for hypertension treatment in Nigeria: a randomized clinical trial. JAMA 2024;332:1070–9.

1. Webster R,
2. Salam A,
3. de Silva HA,
4. et al

.; TRIUMPH Study Group. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA 2018;320:566–79.

1. Williams B,
2. MacDonald TM,
3. Morant S,
4. et al

.; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059–68.

1. Williams B,
2. MacDonald TM,
3. Morant SV,
4. et al

.; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018;6:464–75.

1. Yang C-T,
2. Kor C-T,
3. Hsieh Y-P

. Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease. J Clin Med 2018;7:459.

1. Hundemer GL,
2. Sood MM

. Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management. Pharmacol Res 2021;172:105835.

1. Pitt B,
2. Zannad F,
3. Remme WJ,
4. et al

. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17.

1. Cohen JB,
2. Cohen DL,
3. Herman DS,
4. et al

. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study. Ann Intern Med 2021;174:289–97.

1. Monticone S,
2. Burrello J,
3. Tizzani D,
4. et al

. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017;69:1811–20.

1. Funder JW,
2. Carey RM,
3. Mantero F,
4. et al

. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101:1889–916.

1. Fervers B,
2. Burgers JS,
3. Haugh MC,
4. et al

. Adaptation of clinical guidelines: literature review and proposition for a framework and procedure. Int J Qual Health Care 2006;18:167–76.

1. Brouwers MC,
2. Kho ME,
3. Browman GP,
4. et al

.; AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010;182:E839–42.

1. Whelton PK,
2. Carey RM,
3. Aronow WS,
4. et al

. 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:1269–324.

1. Schünemann HJ,
2. Al-Ansary LA,
3. Forland F,
4. et al

.; Board of Trustees of the Guidelines International Network. Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines. Ann Intern Med 2015;163:548–53.

1. Satheesh G,
2. Dhurjati R,
3. Jha V,
4. et al

. Effectiveness and safety of using standardized treatment protocols for hypertension compared to usual care: a meta-analysis of randomized clinical trials. J Clin Hypertens (Greenwich) 2025;27:e14950.

1. Desai AS,
2. Webb DJ,
3. Taubel J,
4. et al

. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med 2023;389:228–38.

1. Schlaich MP,
2. Bellet M,
3. Weber MA,
4. et al

.; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022; 400:1927–37.

1. Sesa-Ashton G,
2. Nolde JM,
3. Muente I,
4. et al

. Long-term blood pressure reductions following catheter-based renal denervation: a systematic review and meta-analysis. Hypertension 2024;81:e63–70.

1. Khan SS,
2. Matsushita K,
3. Sang Y,
4. et al

.; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American Heart Association’s PREVENT equations [Erratum publié dans Circulation 2024; 149:e956]. Circulation 2024;149:430–49.